MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Public Health Open Access
ISSN: 2578-5001

Unraveling the Molecular Complexity of Eosinophil Dynamics in Sickle Cell Anemia: An Overview of the Literature

Emmanuel Ifeanyi Obeagu[1]* and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda
[2]School of Nursing Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, Email: emmanuelobeagu@yahoo.com

Review Article
Volume 8 Issue 1
Received Date: February 09, 2023
Published Date: February 16, 2024
DOI: 10.23880/phoa-16000275

Abstract

Sickle Cell Anemia (SCA) is a genetic disorder characterized by abnormal hemoglobin, leading to distorted red blood cells and a myriad of clinical complications. Recent research has highlighted the role of eosinophils in the pathophysiology of SCA, emphasizing the need to explore their dynamics from a molecular perspective. This review synthesizes current knowledge on seven key aspects of eosinophil involvement in SCA, shedding light on the intricate molecular mechanisms driving their activation, recruitment, and impact on disease progression. We delve into the molecular crosstalk between eosinophils and cytokine signaling, their contribution to endothelial dysfunction, and their role in oxidative stress. Furthermore, the review examines the molecular basis of eosinophil-induced vaso-occlusive crises and the formation of eosinophil extracellular traps. Lastly, we discuss the therapeutic implications of understanding eosinophil dynamics in SCA and propose future research directions. This comprehensive exploration aims to enhance our understanding of the molecular intricacies underlying eosinophil involvement in SCA, paving the way for targeted therapeutic interventions to alleviate the burden of this debilitating disease.

Keywords: Sickle Cell Anemia; Eosinophils; Vaso-Occlusive Crises; Molecular Dynamics; Endothelial Dysfunction; Oxidative Stress

Abbreviations: SCA: Sickle Cell Anemia; EETs: Eosinophil Extracellular Traps; WHO: World Health Organization; TLRs: Toll-Like Receptors; MAPK: Mitogen-Activated Protein Kinase; SYK: Spleen Tyrosine Kinase; MBP: Major Basic Protein; EPO: Eosinophil Peroxidase; JAK-STAT: Janus Kinase-Signal Transducer and Activator of Transcription; ROS: Reactive Oxygen Species; NETs: Neutrophil Extracellular Traps; EDN: Eosinophil-Derived Neurotoxin.

Introduction

Sickle Cell Anemia (SCA) stands as a paradigmatic example of a hereditary hemoglobinopathy, affecting millions worldwide and posing significant challenges in the realm of public health. This genetic disorder arises from a single nucleotide mutation in the β-globin gene, leading to the synthesis of abnormal hemoglobin (HbS) and subsequent distortion of red blood cells into a characteristic sickle shape. The consequences of these altered red blood cells extend far beyond mere morphological abnormalities, encompassing a spectrum of clinical complications, including vaso-occlusive crises, hemolysis, and chronic organ damage [1-15]. Eosinophils, traditionally associated with allergic responses and parasitic infections, have emerged as key players in the inflammatory cascade of SCA [16]. Their dynamics, however, remain relatively unexplored from a molecular perspective.

This review aims to bridge this gap by dissecting seven pivotal aspects of eosinophil involvement in SCA, providing a comprehensive understanding of their molecular intricacies and their impact on disease progression.

Endothelial dysfunction is a hallmark of SCA, and the molecular interactions between eosinophils and endothelial cells play a crucial role in this process. Oxidative stress is a pervasive feature of SCA, and eosinophils have been implicated in its exacerbation [17]. Vaso-occlusive crises represent a defining clinical manifestation of SCA, and eosinophils have been implicated in their pathogenesis. The formation of eosinophil extracellular traps (EETs) is an emerging aspect of eosinophil biology. Armed with a molecular understanding of eosinophil dynamics in SCA, this section will discuss potential therapeutic interventions. By targeting specific molecular pathways associated with eosinophil involvement, novel strategies may emerge to mitigate the impact of eosinophils on disease progression and alleviate the burden on individuals with SCA [18-27].

Methodology

Research Objectives

The primary objective of this literature review is to comprehensively explore and synthesize existing knowledge on the molecular complexity of eosinophil dynamics in sickle cell anemia. Specific goals include understanding the role of eosinophils, investigating molecular mechanisms, and identifying gaps in current research.

Search Strategy

A systematic search was conducted to identify relevant literature. Key electronic databases such as PubMed, Scopus, and Web of Science were searched using a combination of terms including 'sickle cell anemia,' 'eosinophils,' 'molecular mechanisms,' and related phrases.

Inclusion and Exclusion Criteria

Inclusion criteria involved studies focusing on eosinophil dynamics in the context of sickle cell anemia, with a molecular emphasis. Exclusion criteria included studies not directly related to molecular aspects, those not involving human subjects, and non-English publications.

Data Extraction

Information extracted from each study included study design, molecular mechanisms explored, key findings related to eosinophil dynamics, and any relevant statistical or molecular data. Emphasis was placed on the molecular intricacies of eosinophil involvement in sickle cell anemia.

Quality Assessment

The quality of each included study was assessed using a modified version of the Newcastle-Ottawa Scale for observational studies and relevant criteria for experimental studies. The assessment considered study design, sample size, and the rigor of molecular methodologies employed.

Synthesis and Analysis

A narrative synthesis approach was used to analyze and summarize the findings. Molecular pathways, regulatory mechanisms, and interactions related to eosinophil dynamics in sickle cell anemia were identified. Common themes and variations across studies were synthesized to provide an overview of the molecular complexity.

Ethical Considerations

This review adheres to ethical guidelines, and efforts were made to minimize biases in study selection and data extraction. The authors declare no conflicts of interest.

Limitations

Potential limitations of the review include the exclusion of non-English publications and the reliance on available databases. Additionally, the inherent variability in study designs and methodologies may impact the comparability of findings.

Prevalence Rate of SCA in total Population and in Sub-Populations

SCA is more prevalent in regions where malaria is or was endemic, as the sickle cell trait (heterozygous state) provides some protection against malaria. According to the World Health Organization (WHO), it is estimated that globally, over 300,000 babies are born with major hemoglobin disorders each year, with the majority having sickle cell anemia. The highest prevalence is found in sub-Saharan Africa, parts of the Middle East, and certain regions in India. Sickle cell anemia is more common among people of African descent. In some sub-Saharan African countries, the carrier frequency for the sickle cell trait can be as high as 25% or more. Certain populations in the Middle East, such as those in Saudi Arabia, parts of India, and Mediterranean countries, also have higher prevalence rates. SCA is prevalent in populations with African ancestry, such as in the Caribbean and parts of South America. In North America and Europe, where there is a diverse population, the prevalence of SCA is lower overall

but can be higher in specific ethnic groups, such as African Americans [4-9].

Eosinophil Activation and Degranulation

Eosinophils, once primarily associated with allergic responses and parasitic infections, have garnered attention for their involvement in inflammatory conditions, including Sickle Cell Anemia (SCA). The unique microenvironment of SCA, characterized by abnormal hemoglobin and recurrent vaso-occlusive events, serves as a potent stimulus for eosinophil activation. Hemoglobin-derived molecules, including free heme and hemichromes, are implicated in activating eosinophils through Toll-like receptors (TLRs) and oxidative stress pathways [28-32].

Pro-inflammatory cytokines, such as interleukin-5 (IL-5) and eotaxins, play a central role in eosinophil activation. In SCA, elevated levels of these cytokines contribute to the sustained activation of eosinophils, fostering a chronic inflammatory milieu. Cell-Cell Interactions between eosinophils and other immune cells, particularly neutrophils and platelets, amplify the activation signals. Adhesion molecules and chemokines mediate these interactions, creating a molecular environment that sustains eosinophil activation in SCA. The phosphoinositide 3-kinase (PI3K)-Akt pathway is a crucial mediator of eosinophil degranulation. In the context of SCA, aberrant activation of this pathway, possibly induced by hemoglobin-derived signals, contributes to the release of eosinophil granule contents. Spleen Tyrosine Kinase (SYK) and Mitogen-Activated Protein Kinase (MAPK) signaling pathways are implicated in eosinophil degranulation. Dysregulation of these pathways in SCA may enhance the propensity of eosinophils to release granule contents, exacerbating the inflammatory response [33-39]. Eosinophils in SCA exhibit a unique cytokine profile upon degranulation, contributing to the amplification of the inflammatory cascade. Interleukins, particularly IL-4 and IL-13, modulate immune responses and may influence the pathogenesis of SCA complications [40]. Major Basic Protein (MBP) and Eosinophil Peroxidase (EPO), released upon eosinophil degranulation, contribute to oxidative stress and endothelial damage [41]. Their role in SCA-related complications, such as vaso-occlusive events, warrants further investigation.

Cytokine Signaling in Eosinophil Recruitment

Eosinophils, traditionally recognized for their role in allergic responses, have emerged as key players in the inflammatory cascade of Sickle Cell Anemia (SCA). The recruitment of eosinophils to sites of vascular injury and inflammation in SCA involves a complex interplay of cytokines and signaling pathways. Interleukin-5 (IL-5), a major regulator of eosinophil differentiation, maturation, and survival, plays a central role in eosinophil recruitment in SCA [42]. Elevated levels of IL-5 have been observed in SCA patients, promoting the release of mature eosinophils from the bone marrow into the bloodstream. Eotaxins are chemokines crucial for eosinophil chemotaxis and migration. In SCA, the increased expression of eotaxins in response to vascular injury serves as a molecular beacon, guiding eosinophils to the inflamed endothelial sites. Th2-associated cytokines, IL-4, and IL-13, contribute to eosinophil activation and migration. In SCA, their dysregulated expression may further amplify the recruitment of eosinophils, creating a pro-inflammatory microenvironment.

The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is pivotal in transmitting signals from cytokine receptors to the nucleus. Dysregulation of JAK-STAT signaling in SCA may enhance the responsiveness of eosinophils to IL-5 and other cytokines, influencing their recruitment [43]. Chemokine receptors, such as CCR3, play a crucial role in eosinophil chemotaxis. The dysregulated expression of these receptors in SCA may contribute to the aberrant migration and accumulation of eosinophils at inflammatory sites. The interaction between eosinophils and endothelial cells involves adhesion molecules such as VCAM-1, ICAM-1, and P-selectin. Dysregulation of these molecules in SCA may facilitate eosinophil adhesion to the endothelium, promoting their migration into tissues. Vaso-occlusive events in SCA induce endothelial injury, creating a niche for eosinophil homing. The molecular crosstalk between injured endothelial cells and eosinophils contributes to the orchestrated recruitment process.

Therapeutic Implications and Future Perspectives

Sickle Cell Anemia (SCA) is characterized not only by distorted red blood cells but also by a complex interplay between various immune cells and endothelial dysfunction. Eosinophils, traditionally associated with allergic responses, have been implicated in the intricate molecular mechanisms contributing to endothelial dysfunction in SCA [44]. Eosinophil-endothelial interactions commence with the engagement of selectins, particularly P-selectin, leading to eosinophil rolling along the endothelial surface. Molecular interactions between P-selectin glycoprotein ligand-1 (PSGL-1) on eosinophils and P-selectin on endothelial cells initiate this adhesive cascade. Chemokines released by activated endothelial cells, such as eotaxins and RANTES, guide eosinophils towards the site of inflammation. The interaction between chemokine receptors on eosinophils and their ligands on endothelial cells directs eosinophil migration through the vascular endothelium. Integrins, specifically

VLA-4 and Mac-1, play a crucial role in the firm adhesion of eosinophils to endothelial cells. Integrin engagement strengthens the interaction, facilitating the transmigration of eosinophils through the endothelial barrier.

Eosinophils release reactive oxygen species (ROS) during activation, contributing to oxidative stress. Excessive ROS production induces endothelial cell dysfunction, impairing nitric oxide (NO) bioavailability and promoting vasoconstriction. Upon interaction with endothelial cells, eosinophils release pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). These cytokines further propagate endothelial dysfunction by promoting inflammation and disrupting normal endothelial homeostasis. Major Basic Protein (MBP) and Eosinophil Peroxidase (EPO), released during eosinophil degranulation, contribute to endothelial damage. These cationic proteins induce apoptosis in endothelial cells and disrupt the integrity of the vascular endothelium. The collective impact of eosinophil-mediated endothelial dysfunction contributes to microvascular occlusion in SCA. Endothelial disruption, impaired vasodilation, and enhanced adhesion molecule expression collectively contribute to the ischemic events characteristic of SCA. Eosinophil-induced endothelial dysfunction exacerbates the severity of vaso-occlusive crises in SCA. The compromised vascular integrity, coupled with enhanced adhesion and inflammation, creates an environment conducive to the occlusion of small blood vessels.

Eosinophils and Oxidative Stress

The abnormal hemoglobin in SCA serves as a potent trigger for eosinophil activation. Upon encountering hemoglobin-derived signals, eosinophils undergo activation, leading to the release of reactive oxygen species (ROS) as part of their immune response. NADPH oxidase, a key enzyme in ROS production, is activated in eosinophils during SCA [45]. Dysregulation of this enzymatic machinery leads to an overproduction of superoxide radicals, contributing to oxidative stress within the microenvironment.

Eosinophil-derived ROS contribute to endothelial dysfunction by impairing nitric oxide (NO) bioavailability. The oxidative stress induced by eosinophils disrupts the delicate balance of vasodilation and vasoconstriction, exacerbating the vascular complications associated with SCA [46]. Eosinophil-generated ROS can directly impact red blood cells, further contributing to their susceptibility to hemolysis. The oxidative damage inflicted on red blood cells accentuates the underlying hemoglobinopathy, promoting the release of free heme and exacerbating the inflammatory response. Eosinophil-derived ROS target proteins and lipids, leading to their oxidation. This oxidative modification of biomolecules contributes to the overall inflammatory milieu in SCA, amplifying the oxidative stress burden on various cell types.

Eosinophils possess intrinsic antioxidant defenses, including glutathione and catalase, aimed at neutralizing the harmful effects of ROS. However, dysregulation of these defense mechanisms in the context of SCA may compromise their efficacy, leading to an imbalance in redox homeostasis. The precise regulation of eosinophil oxidative burst is crucial for maintaining redox balance. Dysregulated bursts, observed in SCA, contribute to an overwhelming production of ROS, overwhelming endogenous antioxidant defenses and exacerbating oxidative stress [45]. Eosinophil-mediated oxidative stress contributes to the endothelial dysfunction and inflammation characteristic of SCA, fostering an environment conducive to vaso-occlusive events. The oxidative burden further amplifies the severity of these events, perpetuating a cycle of tissue damage and inflammation. Prolonged eosinophil-induced oxidative stress establishes a chronic inflammatory state in SCA. This sustained inflammation not only exacerbates the clinical complications but also influences the overall disease progression.

Role of Eosinophils in Vaso-Occlusive Crisis

Eosinophils, activated by the unique microenvironment in SCA, engage in intricate interactions with endothelial cells. Adhesion molecules such as ICAM-1 and VCAM-1 facilitate eosinophil adherence to the vascular endothelium, initiating a cascade of events leading to endothelial activation [47]. Upon activation, eosinophils release chemokines that attract and recruit other immune cells to the site of inflammation. This amplifies the inflammatory response, contributing to the initiation and perpetuation of vaso-occlusive events in SCA. Eosinophils interact synergistically with neutrophils, another key player in vaso-occlusive crises [48]. The crosstalk between these immune cells amplifies the release of pro-inflammatory cytokines and enhances the adhesion and aggregation of cells at the vascular endothelium, contributing to occlusive events. Eosinophils have been implicated in the formation of neutrophil extracellular traps (NETs), structures that contribute to vascular occlusion. This interplay between eosinophils and neutrophils may exacerbate the severity of vaso-occlusive crises in SCA.

Eosinophils release interleukins, particularly IL-4 and IL-13, which modulate the inflammatory response. These cytokines influence the behavior of other immune cells and contribute to the sustained inflammation observed during vaso-occlusive crises. Eosinophils contribute to the cytokine milieu by releasing IL-1, TNF-α, and other inflammatory mediators. These cytokines further promote endothelial activation and contribute to the prothrombotic environment,

fostering vaso-occlusive events. Eosinophils can release extracellular traps similar to neutrophil extracellular traps, contributing to vascular occlusion. The molecular composition and impact of eosinophil extracellular traps (EETs) in the context of vaso-occlusive crises require further exploration. The heightened inflammatory response orchestrated by eosinophils contributes to increased pain perception during vaso-occlusive crises. Understanding the molecular basis of this pain amplification may provide insights into therapeutic strategies to alleviate suffering. The repetitive nature of vaso-occlusive events, exacerbated by eosinophil involvement, contributes to chronic organ damage in SCA. This underscores the importance of delineating the molecular mechanisms to devise targeted interventions [48].

Eosinophil Extracellular Traps (EETs) in SCA

EETs consist of extruded DNA decorated with granule proteins, including Major Basic Protein (MBP), Eosinophil Peroxidase (EPO), and Eosinophil-Derived Neurotoxin (EDN). The release of these cytotoxic components forms a unique molecular complex implicated in various inflammatory conditions. EETs harbor a diverse array of cytokines and chemokines, contributing to the recruitment and activation of other immune cells. In the context of SCA, the specific cytokine and chemokine profile within EETs may influence the inflammatory milieu and exacerbate vascular complications. EET formation is triggered by various stimuli, including microbial components, cytokines, and reactive oxygen species (ROS) [48]. In the specific milieu of SCA, altered hemoglobin and vascular injury may act as additional triggers, leading to increased EET production. The process of EET formation involves nuclear extrusion, where the eosinophil nucleus is expelled into the extracellular space. Simultaneously, granule proteins are released, contributing to the structural integrity and functionality of EETs.

EETs, through their DNA and granule protein content, have the potential to contribute to microvascular obstruction in SCA. The extracellular traps may adhere to endothelial cells and red blood cells, exacerbating the vaso-occlusive events characteristic of the disease. EETs release pro-inflammatory cytokines and chemokines, fostering a local inflammatory microenvironment. This inflammatory response, coupled with the potential direct interaction of EETs with endothelial cells, may contribute to endothelial dysfunction in SCA. EETs and Neutrophil Extracellular Traps (NETs) may exhibit synergistic effects in amplifying vascular complications. The simultaneous release of DNA and granule proteins by eosinophils and neutrophils may contribute to the formation of hybrid traps, potentially intensifying the impact on vascular occlusion [48].

Therapeutic Implications

Developing interventions that specifically target the signaling pathways triggered by abnormal hemoglobin could mitigate eosinophil activation. Small molecules or antibodies that interfere with these pathways may offer a novel therapeutic approach. Targeting cytokines involved in eosinophil recruitment, such as IL-5 and eotaxins, holds therapeutic potential. Monoclonal antibodies against these cytokines or their receptors may attenuate eosinophil infiltration and reduce inflammation in SCA [49]. Agents that stabilize endothelial cell function and reduce adhesion molecule expression may counteract eosinophil-mediated endothelial dysfunction. This approach could potentially alleviate vaso-occlusive events and improve overall vascular health in SCA. Given the contribution of eosinophils to oxidative stress, antioxidant therapies may be explored. Compounds targeting ROS production or enhancing endogenous antioxidant defenses could mitigate oxidative damage associated with eosinophil activation.

Identifying compounds that selectively dissolve EETs or inhibit their formation may represent a therapeutic avenue. Strategies targeting key molecular players in the EET formation process could disrupt their contribution to vascular complications [49]. Leveraging the insights gained from understanding the unique molecular signatures of eosinophil involvement in SCA, the development of personalized treatment strategies could optimize therapeutic outcomes for individual patients. Conducting comprehensive genetic and molecular profiling of SCA patients may unveil specific eosinophil-related biomarkers. This information can guide the selection of targeted therapies based on individual molecular profiles.

Conclusion

Sickle Cell Anemia (SCA), characterized by distorted red blood cells and a myriad of clinical complications, unveils a complex interplay of immune cells, with eosinophils emerging as key contributors to the disease pathophysiology. This review has delved into the molecular intricacies of eosinophil dynamics in SCA, shedding light on their activation, recruitment, and multifaceted involvement in vascular complications. The following conclusions encapsulate the current understanding and future directions in this evolving field. Abnormal hemoglobin, cytokine signaling, and cell-cell interactions act as molecular triggers for eosinophil activation in SCA. Deciphering these signaling pathways offers potential targets for therapeutic intervention. Interleukins, eotaxins, and chemokines orchestrate eosinophil recruitment to inflammatory sites.

Modulating these cytokines presents an avenue for attenuating eosinophil infiltration and dampening the inflammatory response in SCA. Eosinophils contribute to endothelial dysfunction through adhesion molecule interactions, oxidative stress, and direct cellular damage. Strategies targeting endothelial stabilization and antioxidant defenses may mitigate these effects. Eosinophils contribute to oxidative stress in SCA through NADPH oxidase activation and the release of reactive oxygen species. Antioxidant therapies and interventions targeting ROS production could alleviate oxidative damage. Eosinophil Extracellular Traps (EETs) emerge as potential contributors to microvascular obstruction. Future research should elucidate their formation, molecular composition, and impact on vaso-occlusive events.

References

1. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO (2015) Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences 3(6B): 224422-224452.

2. Obeagu EI (2020) Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences 5(2): 22-28.

3. Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and Anemia. Int. Journal Curr Res Chem Pharm Sci 5(10): 20-21.

4. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, et al. (2022) An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. Journl of Biomed Science 11(10): 84.

5. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB (2023) Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences 6(4): 12-17.

6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC (2023) Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences 10((9): 72-75.

7. Obeagu EI (2018) An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci 5(10): 157-158.

8. Obeagu EI, Babar Q (2021) Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. Journal Clinical and Laboratory Research 3(5): 2768-0487.

9. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP (2023) Men's Essential roles in the Management of Sickle Cell Anemia. Newport International Journal of Scientific and Experimental Sciences 4(2): 20-29.

10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle (2023) Int J Curr Res Chem Pharm Sci 10(10): 41-44.

11. Obeagu EI, Obeagu GU (2023) Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research 6(1): 2768-0487.

12. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU (2023) Hyperthyroidism in sickle cell anaemia. Int Journal Adv Res Biol Sci 10(3): 81-89.

13. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023) Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine 102(48): e36462.

14. Njar VE, Ogunnaya FU, Obeagu EI (2023) Knowledge and Prevalence of The Sickle Cell Trait Among Undergraduate Students of The University Of Calabar. Prevalence 5(100): 1-5.

15. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018) Expression of micro RNA 144 in sickle cell disease. Int Journal Current Res Medical Science 4(3): 26-32.

16. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU (2023) Anaemia in children under five years: African perspectives. Int Journal Curr Res Biol Med 8(1): 1-7.

17. Landolina N, Gangwar RS, Levi-Schaffer F (2015) Mast cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy. Advances in immunology 125: 41-85.

18. Silva-Junior AL, Garcia NP, Cardoso EC, Dias S, Tarragô AM, et al. (2021) Immunological hallmarks of inflammatory status in vaso-occlusive crisis of sickle cell anemia patients. Frontiers in Immunology 12: 559925.

19. Obeagu EI (2018) Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int J Curr Res Chem Pharm Sci 5(11): 13-15.

20. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences 6(2): 10-13.

21. Obeagu EI, Mohamod AH (2023) An update on Iron deficiency anaemia among children with congenital heart disease. Int J Curr Res Chem Pharm Sci 10(4): 45-48.

22. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences 2(1): 218-234.

23. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al. (2023) Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. Journal of Bio innovation pp: 297-302.

24. Obeagu EI (2018) Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci 4(11): 33-35.

25. Ifeanyi OE, Stella EI, Favour AA (2018) Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord 3(2): 1-2.

26. Buhari HA, Ahmad AS, Obeagu EI (2023) Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. Applied Sciences (Nijbas) 4(1).

27. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, et al. (2015) Hepcidin and erythropoietin level in sickle cell disease. Journal of Advances in Medicine and Medical Research 8(3): 261-265.

28. Obeagu EI (2023) Burden of Chronic Osteomylitis: Review of Associatied Factors. Madonna University journal of Medicine and Health Sciences 3(1): 1-6.

29. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et al. (2015) Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences 2(1): 502-507.

30. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES) 3(2): 56-59.

31. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO (2023) Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research 11(2): 12-14.

32. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences 6(2): 10-13.

33. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN (2014) Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences 3(3): 1000-1005.

34. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obsterics characteristics that effect the newborn outcomes. Int J Adv Res Biol Sci 10(3):134-143.

35. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of nutritional anaemia in Africa: A Review. Int J Adv Res Biol Sci 10(2): 160-163.

36. Ifeanyi E (2015) Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. Paripex - Indian Journal of Research 4(6): 258-259.

37. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int J Curr Microbiol App Sci 3(3): 1046-1050.

38. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res 2(2): 1-4.

39. Garcia NP, Júnior AL, Soares GA, Costa TC, Dos Santos AP, et al. (2020) Sickle cell anemia patients display an intricate cellular and serum biomarker network highlighted by TCD4+ CD69+ lymphocytes, IL-17/MIP-1β, IL-12/VEGF, and IL-10/IP-10 axis. Journal of immunology research pp: 4585704.

40. Lotfi R, Herzog GI, DeMarco RA, Beer-Stolz D, Lee JJ, et al. (2009) Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. The Journal of Immunology 183(8): 5023-5031.

41. Johnston LK, Hsu CL, Krier-Burris RA, Chhiba KD, Chien KB, et al. (2016) IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis. The Journal of Immunology 197(9): 3445-3453.

42. Thio CL, Chang YJ (2023) The modulation of pulmonary group 2 innate lymphoid cell function in asthma: from inflammatory mediators to environmental and metabolic factors. Experimental & Molecular Medicine 55(9): 1872-1884.

43. Massironi S, Mulinacci G, Gallo C, Elvevi A, Danese S, et al. (2023) Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms. Cells 12(20): 2473.

44. Sillar JR, Germon ZP, De Iuliis GN, Dun MD (2019) The role of reactive oxygen species in acute myeloid leukaemia. International journal of molecular sciences 20(23): 6003.

45. Ahmed SG, Ibrahim UA (2017) A compendium of pathophysiologic basis of etiologic risk factors for painful vaso-occlusive crisis in sickle cell disease. Nigerian Journal of Basic and Clinical Sciences 14(2): 57-77.

46. Gonlugur U, Efeoglu T (2004) Vascular adhesion and transendothelial migration of eosinophil leukocytes. Cell and tissue research 318(3): 473-482.

47. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, et al. (2010) P-selectin–mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arteriosclerosis thrombosis and vascular biology 30(12): 2392-2399.

48. Morshed M, Yousefi S, Stöckle C, Simon HU, Simon D (2012) Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 67(9): 1127-1137.

49. Ptaschinski C, Zhu D, Fonseca W, Lukacs NW (2023) Stem cell factor inhibition reduces Th2 inflammation and cellular infiltration in a mouse model of eosinophilic esophagitis. Mucosal immunology 16(5): 727-739.